Imaging of Sarcopenia in Type 2 Diabetes Mellitus
Dingyue Wang,Gaosen Zhang,Yana Yu,Zhen Zhang
DOI: https://doi.org/10.2147/cia.s443572
IF: 3.829
2024-01-27
Clinical Interventions in Aging
Abstract:Dingyue Wang, Gaosen Zhang, Yana Yu, Zhen Zhang Department of Ultrasound, the First Affiliated Hospital China Medical University, Shenyang City, Liaoning Province, 110001, People's Republic of China Correspondence: Zhen Zhang, Email Sarcopenia is an age-related condition characterized by the loss of skeletal muscle mass, muscular strength, and muscle function. In older adults, type 2 diabetes mellitus (T2DM) constitutes a significant health burden. Skeletal muscle damage and deterioration have emerged as novel chronic complications in patients with diabetes, often linked to their increased longevity. Diabetic sarcopenia has been associated with increased rates of hospitalization, cardiovascular events, and mortality. Nevertheless, effectively managing metabolic disorders in patients with T2DM through appropriate therapeutic interventions could potentially mitigate the risk of sarcopenia. Utilizing imaging technologies holds substantial clinical significance in the early detection of skeletal muscle mass alterations associated with sarcopenia. Such detection is pivotal for arresting disease progression and preserving patients' quality of life. These imaging modalities offer reproducible and consistent patterns over time, as they all provide varying degrees of quantitative data. This review primarily delves into the application of dual-energy X-ray absorptiometry, computed tomography, magnetic resonance imaging, and ultrasound for both qualitative and quantitative assessments of muscle mass in patients with T2DM. It also juxtaposes the merits and limitations of these four techniques. By understanding the nuances of each method, clinicians can discern how best to apply them in diverse clinical scenarios. Keywords: diagnostic imaging, older adults, sarcopenia, skeletal muscle mass, type 2 diabetes mellitus Sarcopenia, a syndrome characterized by the deterioration of muscle mass and function (including muscle strength and/or physical performance) as individuals age, has emerged as a pressing global concern. This is attributed to its association with escalated risks of mortality, frailty, and diminished mobility among the older adults. 1,2 Type 2 diabetes mellitus (T2DM) is one of the most prevalent metabolic disorders, affecting almost a quarter of the population aged 65 years and above. This proportion is anticipated to escalate in the forthcoming decades. 3 Older adults grappling with T2DM experience elevated incidences of functional disability, coexisting ailments, and various geriatric conditions, alongside microvascular and macrovascular complications. 4 A novel chronic complication of T2DM is the damage and degeneration of the skeletal muscle, which is attributed to the extended survival of patients with T2DM. 5,6 The vulnerability to sarcopenia is notably augmented in patients with T2DM. T2DM is associated with excessive loss of skeletal muscle and trunk fat mass in older adults. Older women withT2DM are at especially high risk for loss of skeletal muscle mass. 7 While the rate of deterioration might vary contingent on the muscle cluster, it invariably leads to compromised muscle. 8 The interplay between these two factors may potentiate adverse outcomes, notably functional regression and disability. 9 The decline in muscle mass seems to be an inevitable part of the aging trajectory, and variations in the rate of degeneration among different populations imply that modifiable behavioral elements can influence the onset of sarcopenia. 10 A particularly effective strategy in thwarting sarcopenia is resistance-based training. 11 Moreover, alongside lifestyle modifications, due consideration must be accorded to several hypoglycemic drugs, which could yield varied effects on the underlying pathophysiological irregularities giving rise to sarcopenia. Our investigation delves into pertinent reviews on this subject, aimed at facilitating the early clinical identification of susceptibility to sarcopenia in patients with T2DM and the timely initiation of interventions to ameliorate muscle mass loss. This proactive approach seeks to minimize the incidence of falls and fractures in patients with T2DM, consequently enhancing their quality of life. Furthermore, it aids medical practitioners in selecting appropriate imaging modalities to track alterations in the muscle structure and mass among patients with T2DM during the course of diabetes. This monitoring process is vital for evaluating the efficacy of relevant treatments. Age-related loss of muscle mass and function is a prevalent phenomenon. Muscle strength undergoes a reduction of 20–40% during the seventh and eighth decades of life, and this decline exacerbates progressively over time. 12 In 1988, Irwin Rosenberg first introduced the term "sarcopenia" to del -Abstract Truncated-
geriatrics & gerontology,gerontology